Merck and NGM will continue their research, discovery and development collaboration with a narrower scope, focused primarily on retinal and cardiovascular and metabolic (CVM) targets of interest to Merck Merck will continue to advance MK-3655, an FGFR1c/KLB agonistic antibody, currently […]
